Abstract
Abstract Noncovalent bonds typically mediate interactions between a T cell receptor (TCR) and a peptide-major histocompatibility complex (pMHC) ligand. In this study, we describe a novel mechanism involving a covalent TCR-pMHC interaction through a cysteine-cysteine disulfide bond. By introducing cysteine resodues into the TCR CDR3 and into the peptide of a known TCR-pMHC combination, we show that this disulfide bond formation does not require structural rearrangement and can still occur even when the initial affinity of the TCR-pMHC interaction is low. This mechanism strongly activates TCR signaling and has potential applications in basic immunology to further our fundamental understanding of T cell activation/differentiation as well as applied clinically for improving the efficacy and sensitivity of adoptive T cell therapies. Our findings shed new light on T cell activation and provide additional avenues for the development of modern immunotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.